Can a targeted drug help breast cancer patients with 'invisible' HER2?
NCT ID NCT01975142
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 155 people with metastatic breast cancer whose original tumors were HER2-negative. Researchers checked their blood for HER2-positive cancer cells. Those who had them received the drug T-DM1, which delivers chemotherapy directly to HER2-positive cells. The goal was to see if the tumors would shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab-emtansine (T-DM1)
What this could lead to
If it works, this could offer a treatment option for people with metastatic breast cancer whose tumors test HER2-negative but have HER2-positive cells in their blood.
What could go wrong
This is a small, early-phase trial with no comparison group, so results may not apply widely. T-DM1 can cause side effects like liver damage and low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Catherine de Sienne
Vandœuvre-lès-Nancy, 54519, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre Val d'Aurelle - P. Lamarque
Montpellier, 34298, France
-
Chu Saint-Louis
Paris, 75475, France
-
Chu de Limoges
Limoges, 87042, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Institut Curie
Paris, 75005, France
-
Institut Curie - Hôpital René HUGENIN
Saint-Cloud, SAINT-CLOUD, France
-
Institut de Cancérologie HARTMANN
Levallois-Perret, 92309, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France